Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Dextrose + electrolyte no. 48** is a sterile, nonpyrogenic **intravenous crystalloid replacement solution** containing dextrose with a defined electrolyte mixture, classified as **Multiple Electrolytes and Dextrose Injection, Type 1, USP**. The formulation provides water, electrolytes, and calories and is used for **fluid and electrolyte replenishment** and as an **alkalinizing agent**. Per 100 mL, it contains dextrose hydrous, sodium lactate, potassium chloride, magnesium chloride, monobasic potassium phosphate, and sodium chloride. Its effect is not mediated through a single molecular target; rather, it acts as a **supportive replacement therapy** that restores intravascular and extracellular fluid composition, supplies carbohydrate calories, and helps correct acid-base and electrolyte deficits. The product has been manufactured by **Baxter Healthcare**.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextrose + electrolyte no. 48.